Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term MND-2119 (icosapent) therapy and triglyceride reduction
jRCT2080225009Phase 3Completed
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of icosapent in hyperlipidemia. Primary endpoints: Long-term safety of MND-2119 (icosapent) and Change in serum triglyceride (TG) levels. Started Jan 2020; status: completed.
02
Drugs
icosapent
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on jRCT2080225009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225009.